

CORPORATE PROFILE


AXIM Biotechnologies is an innovative biotechnology company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products as well as alternative sources of energy. We prioritize the well-being of our customers while embracing a solid fiscal strategy. We believe to be setting the green standard for cannabinoid bioscience through the discovery and commercialization of new materials and technologies for healthy living, all while respecting the environment.

5 Rockefeller Plaza
20th Floor
New York, NY 10111
Phone: (212) 751-0001
<http://www.aximbiotech.com>
Info@aximbiotech.com

Grayling
101 Avenue of the Americas
8th Floor
New York, NY 10013
(646) 284 9474
shiwei.yin@grayling.com
lucia.domville@grayling.com

STOCK PERFORMANCE

| | |
|----------------------------|--------------|
| Symbol | AXIM |
| Exchange | OTCQB |
| Market Cap. | 323.83m |
| 52 Week Range | 0.21 - 19.80 |
| Close | 6.38 |
| Volume | 4 |
| Shares Outstanding | 52,569,441 |
| As of Sep 22, 2017 4:24 pm | |



MANAGEMENT TEAM

Dr. George E. Anastassov – Chief Executive Officer

Dr. Philip. A. Van Damme – Chief Scientific/Medical Officer

Lekhram Changoer – Chief Technology Officer

RECENT HEADLINES

[Sep 13, 2017 - Biosynthesis Technology Could Transform Cannabinoid Production](#)

[Sep 11, 2017 - How to Capitalize on the \\$1 Billion Hemp Industry -- CFN Media](#)

[Sep 7, 2017 - AXIM Biotech to Present at Rodman & Renshaw 19th Annual Global Investment Conference in New York City](#)

[Aug 31, 2017 - How Cannabis Could Solve the Opioid Crisis -- SECFilings.com](#)

[Aug 22, 2017 - AXIM Biotechnologies Reports Second Quarter 2017 Results](#)